Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13954730 | 1.00 | TACR1 (1.00) | TACR1 | |
| SCHEMBL13934970 | 0.92 | TACR1 (1.00) | TACR1 | |
| SCHEMBL4469839 | 0.90 | TACR1 (0.81) | TACR1 | |
| SCHEMBL4457761 | 0.85 | TACR1 (0.84) | TACR1 | |
| SCHEMBL4465613 | 0.83 | TACR1 (0.80) | TACR1 | |
| SCHEMBL5327979 | 0.83 | TACR1 (0.70) | TACR1 | |
| SCHEMBL4459415 | 0.82 | TACR1 (0.86) | TACR1 | |
| SCHEMBL4458723 | 0.81 | TACR1 (0.78) | TACR1 | |
| SCHEMBL4461096 | 0.81 | TACR1 (0.76) | TACR1 | |
| SCHEMBL4460535 | 0.80 | TACR1 (0.75) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-11-19 | — | — | US | disclosed |
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| EP-1978965-A2 | HEXAHYDRO-3H-PYRROLIZIN-3-ONES USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007136570-A2 | 5,6-FUSED PYRROLIDINE COMPOUNDS USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007087224-A2 | HEXAHYDRO-3H-PYRROLIZIN-3-ONES USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | TACR1, PROKR1, TACR2 | TACR1 1/4885 |
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.